Considering the advantages of EVs with high physicochemical stability and biocompatibility, low toxicity, and immunogenicity [34], using engineered EVs to deliver siRNA targeting GNG5 may represent a novel approach for AD intervention, distinct from direct Aβ clearance and γ-secretase inhibition. Here, GNG5 is linked to Alzheimer disease.